The sandwich therapy showed a 2-year overall survival rate of 97% and a leukemia-free survival rate of 72% in Ph-negative ...

Following the first Phase 3 study of HyBryte(TM) for the treatment of CTCL, the FDA and the EMA indicated that they would require a second successful Phase 3 trial to support mark ...

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing ...

Kazia Therapeutics Limited (Nasdaq: KZIA), an oncology-focused drug development company, today announced that a patient with stage IV triple-negative breast cancer (TNBC) treated under an ...

LINTS, a non-masking low-intensity noise tuned to each patient’s tinnitus frequency, produced statistically significant but ...

Bristol Myers Squibb (NYSE:BMY) in collaboration with Johnson & Johnson today announced the decision to stop the Phase 3 Librexia ACS trial evaluating the efficacy and safety of milvexian when added ...

In a phase 1 trial, a gene-editing therapy that targets ANGPTL3 was associated with few serious adverse events and at higher ...

According to the company, this study is the third positive trial for Gazyva/Gazyvaro for treating immune-mediated conditions, following the trials with lupus nephritis (REGENCY) a ...

Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 ...

Jazz Pharmaceuticals Plc (NASDAQ:JAZZ) shares are popping on Monday following the company's positive results of its Phase 3 HERIZON-GEA-01 trial, which assessed Ziihera in combination with ...

MALVERN, PA — Annovis Bio, Inc. (NYSE: ANVS) announced that all 84 clinical sites in its pivotal Phase 3 study for early ...

The movie from French filmmaker Alexis Lloyd world premieres at the Naples International Film Festival. By Georg Szalai Global Business Editor “This, of course, doesn’t sit well with members of the ...